Eluvia banner image

ELUVIA VS. BMS VS. DCB

SPORTS randomized controlled trial results.

SPORTS randomized controlled trial results​

SPORTS is the first investigator-sponsored, core-lab adjudicated, prospective, multi-centre, three-arm RCT comparing outcomes of DES (EluviaTM) vs. BMS (investigator choice) vs. DCB (SeQuent Please), 1:1:1, in TASC C/D lesions.1  Eluvia DES proved statistically superior to BMS in long, complex lesions.

SPORTS RCT met the primary endpoint showing superior percentage diameter stenosis results

Eluvia demonstrated statistically superior performance over BMS, whilst DCB was only non-inferior to BMS when evaluated angiographically for percent diameter stenosis and late lumen loss at 12 months.

1 year angiographic diameter stenosis
1 Year angiographic diameter stenosis chart

Eluvia DES confirmed superior primary patency results over 24 months.*

1 and 2 year primary patency
Graph of 1-year and 2-year primary patency.

Late lumen loss and freedom from CD-TLR differed statistically across groups, favoring Eluvia DES

1 and 2 year freedom from CD-TLR
1-year late lumen loss; 2-year freedom from CD-TLR.

SPORTS randomized controlled trial details​

Eluvia DES​ (n=74)​DCB​ (n=74)​BMS​ (n=76)​p-value​
Average diameter stenosis in lesion​25.3%​53.7%​60.0%​<0.0001​
Average late lumen loss​0.4mm​1.1mm​2.0mm​<0.0001​
1 Year K-M freedom from CD-TLR ​94.5%​80.7%​77.4%​0.015​
2 Year K-M freedom from CD-TLR ​85.5%75.0%​63.8%​0.05​

Ordering and reimbursement

Get downloads for ordering information and reimbursement coding guides for our drug-eluting technologies.

Stay up to date

Receive emails about the latest drug-eluting technology news, innovations and events in your area.

References:

* Tepe, G. SPORTS Trial: Drug Eluting Stent or Primary Bare Nitinol Stent Application versus Drug Coated Balloons in Long SFA Lesions. Presented at Charing Cross 23 Apr 2025.

  1. Tepe G. SPORTS. TCT 2023, October 24, 2023, San Francisco, CA.​
  2. Imperial: Gray WA, Keirse K, Soga Y, et al; IMPERIAL investigators. A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomized, non-inferiority trial. Lancet. 2018;27;392(10157):1541–1551. Müller-Hülsbeck S, Benko A, Soga Y, et al. Two-year efficacy and safety results from the IMPERIAL Randomized study of the Eluvia polymer-coated drug-eluting stent and the Zilver PTX polymer-free drug-coated stent. Cardiovasc Intervent Radiol. 2021;44:368–375
  3. EMINENT: Gouëffic Y, Torsello G, Zeller T, et al; EMINENT Investigators. Efficacy of a drug-eluting stent versus bare metal stents for symptomatic femoropopliteal peripheral artery disease: Primary results of the EMINENT randomized trial. Circulation. 2022;146:1564–1576.
  4. Majestic: Müller-Hülsbeck S, Charing Cross 2015. Müller-HülsbeckS, et al. Cardiovasc Intervent Radiol. 2017;40(12):1832–1838.
  5. Regal: Lansik W. Real world all comers data from the REGAL registry – 2-year results. Presented at LINC 2023.
  6. Auckland: Holden, A. Single Centre Long-Term Experience with the Boston Scientific Eluvia DES in Femoro-popliteal Artery Occlusive Disease. LINC 2020.
  7. IMPERIAL Long: Müller-Hülsbeck S, Benko A, Soga Y, et al. Two-Year Efficacy and Safety Results from the IMPERIAL Randomized Study of the Eluvia Polymer-Coated Drug-Eluting Stent and the Zilver PTX Polymer-free Drug-Coated Stent. Cardiovasc Intervent Radiol. 2021;44(3):368–375. 
  8. Capsicum: Iida O, Takahara M, Soga Y, et al; CAPSICUM Investigators. 1-Year Outcomes of Fluoropolymer-Based Drug-Eluting Stent in Femoropopliteal Practice: Predictors of Restenosis and Aneurysmal Degeneration. JACC Cardiovasc Interv. 2022 Mar 28;15(6):630–638. Iida LINC 2023.
  9. Desafinado: Kum S, Ipema J, Huizing E, et al. Outcomes of the paclitaxel-eluting Eluvia stent for long femoropopliteal lesions in Asian patients with predominantly chronic limb-threatening ischemia. Vasc Med. 2021;26(3):267–272.
  10. Muenster: Stavroulakis K, Torsello G, Bosiers M. 2-Year Outcomes of the Eluvia Drug-Eluting Stent for the Treatment of Complex Femoropopliteal Lesions. JACC Cardiovasc Interv. 2021;14(6):692–701.
  11. Ultimate: Ichihashi S, Takahara M, Yamaoka T, et al. Drug eluting versus covered stent for femoropopliteal artery lesions: Results of the ultimate study. Eur J Vasc Endovasc Surg. 2022;64(4);359–366

 

Caution:
The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.